Related Experiment Video
Updated: Apr 30, 2026
10:26
Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
5.1K
Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported?
Constantin A Dasanu1, Bruno Bockorny2
1Department of Hematology-Oncology, St. Francis Hospital and Medical Center, Hartford, CT, USA c_dasanu@yahoo.com.
Summary
Gemcitabine chemotherapy can cause pseudocellulitis, a skin reaction mimicking infection. Recognizing this underreported side effect avoids unnecessary antibiotic treatment for pancreatic cancer patients.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Gemcitabine is a widely used chemotherapy agent for various cancers, including pancreatic cancer.
- Pseudocellulitis is a known but underreported adverse reaction associated with gemcitabine therapy.
- The condition is hypothesized to result from vascular toxicity and increased capillary permeability in the skin.
Observation:
- This report details a case of recurrent pseudocellulitis in a patient undergoing gemcitabine treatment for metastatic pancreatic cancer.
- The patient experienced recurring skin reactions consistent with pseudocellulitis.
- The clinical presentation mimicked infectious cellulitis.
Findings:
- Gemcitabine-induced pseudocellulitis is likely underrecognized in clinical practice.
- Misdiagnosis as cellulitis can lead to inappropriate and costly antibiotic treatment.
- The diagnosis of pseudocellulitis is primarily clinical.
Implications:
- Increased awareness among oncologists and non-oncology providers is crucial for accurate diagnosis and patient management.
- Avoiding misdiagnosis prevents unnecessary antibiotic use and associated healthcare costs.
- Proper identification allows for patient reassurance and avoids potentially harmful interventions.